EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection

Xiaoqing Fan iD, Kangna Cao, Xilin Wu iD, Xiaoyu Yan iD

Microbiology Spectrum · 04.11.2025 · 13 (11)

DOI: 10.1128/spectrum.00805-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.11.2025. Verfasst von Xiaoqing Fan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China. Hauptthemen laut MEDLINE: HIV-1, Single-Domain Antibodies, HIV Infections, CD4 Antigens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nb 457 is a novel anti-CD4 nanobody derived from a CD4-immunized alpaca, exhibiting high potency and broad-spectrum activity against HIV-1. This study aims to use pharmacokinetic-pharmacodynamic (PK-PD) modeling that characterizes the time-course of Nb 457 trimeric nanobody Nb 457 -Nb HSA -Nb 457 and viral load in mice. The serum concentrations of Nb 457 -Nb HSA -Nb 457 and HIV-1 load were modeled using a target-mediated drug disposition (TMDD) PK-PD model following intraperitoneal and subcutaneous administration of 400 µg in mice. All model parameters were estimated with high precision, with relative standard errors below 50%. The TMDD PK-PD model successfully captured the observed PK/PD profiles, demonstrating the strong therapeutic potential of Nb 457 -Nb HSA -Nb 457 for HIV-1 treatment. Furthermore, the model was extrapolated to assess the feasibility of Nb 457 -Nb HSA -Nb 457 for HIV-1 treatment in humans. The simulated viral growth trajectories at a dose of 20 mg/kg once every 2 days resulted in a downward trend in the slope of the viral trajectory, suggesting a failure to maintain replication and ultimately leading to viral suppression. Additionally, increasing the dosage or frequency of administration could further enhance the inhibition of viral replication. The simulated human PK-PD supports Nb 457 -Nb HSA -Nb 457 as a promising anti-HIV-1 agent. This mechanistic TMDD PK-PD model provides a valuable tool to support the clinical development of Nb 457 -Nb HSA -Nb 457 by enabling simulations of various dosing strategies to evaluate its efficacy and safety. IMPORTANCE HIV-1 continues to pose a global health crisis, with millions of individuals depending on lifelong antiretroviral therapy, which faces significant challenges such as drug resistance and adherence issues. Nanobodies, which are small antibody fragments, present a promising alternative due to their high specificity, stability, and ease of production. Our study introduces Nb457-NbHSA-Nb457, a novel trimeric nanobody engineered to block HIV-1 entry by binding to CD4, the primary receptor for the virus. Using advanced pharmacokinetic-pharmacodynamic modeling, we predict the behavior of this therapy in humans, effectively bridging preclinical findings to clinical application. This research not only advances a new class of HIV therapeutics but also establishes a framework to expedite the development of nanobody-based drugs for infectious diseases, offering hope for simpler and more effective treatments to combat the pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Single-Domain AntibodiesHIV InfectionsCD4 AntigensAnti-HIV AgentsAntibodies, NeutralizingHIV AntibodiesBroadly Neutralizing AntibodiesAnimalsMiceHumansViral LoadCamelids, New WorldFemale

Stichwörter der Autor:innen

HIV-1Nb457-NbHSA-Nb457anti-CD4 nanobodypharmacokinetic-pharmacodynamic modelingtarget-mediated drug disposition

Substanzen

Single-Domain AntibodiesCD4 AntigensAnti-HIV AgentsAntibodies, NeutralizingHIV AntibodiesBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China.
  • Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmacy, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China.
  • Center for Public Health Research, Medical School, Nanjing University, Nanjing, People's Republic of China.
  • Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, People's Republic of China.
  • State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, People's Republic of China.

ORCID-Profile: Xiaoqing Fan, Xilin Wu, Xiaoyu Yan

Zitieren

APA

Fan, X., Cao, K., Wu, X., & Yan, X. (2025). Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection. Microbiology Spectrum, 13(11). https://doi.org/10.1128/spectrum.00805-25

Vancouver

Fan X, Cao K, Wu X, Yan X. Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection. Microbiology Spectrum. 2025;13(11). doi:10.1128/spectrum.00805-25

BibTeX
@article{Fan2025,
  author = {Fan, Xiaoqing and Cao, Kangna and Wu, Xilin and Yan, Xiaoyu},
  title = {Pharmacokinetic-pharmacodynamic modeling of a highly potent and broadly neutralizing anti-CD4 trimeric nanobody to inhibit HIV-1 infection},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {11},
  doi = {10.1128/spectrum.00805-25}
}
Kostenlos starten →